Literature DB >> 19455675

OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.

Naomi Kitamura1, Satoshi Murata, Tomoyuki Ueki, Eiji Mekata, R Todd Reilly, Elizabeth M Jaffee, Tohru Tani.   

Abstract

Regulatory T cells (Tregs) play an important role in maintaining immunological tolerance that is one of the main obstacles to overcome for improving antitumor immunity. Recently, the Treg has been shown to constitutively express OX40 (CD134), which is a member of the TNF-receptor family that is transiently expressed on effector T cells after TCR triggering, and through which the signal enhances effector T-cell proliferation and memory T-cell development. However, little is known about the role of OX40 costimulation to Tregs in tumor immunology. Here we show that OX40 signaling modulates the function of naturally occurring Tregs in vitro and in vivo. Foxp3 expression on Tregs was reduced by OX40 costimulation, but not by IL-2 stimulation. Tregs suppressed the proliferation of naïve CD4(+) CD25(-) T cells after TCR triggering, in contrast, OX40 costimulated Tregs that reduced Foxp3 expression reversed the suppressive function. In addition, Tregs inhibited the proliferation of TCR-stimulated (primed) CD4(+) T cells and naïve CD8(+) T cells after TCR-mediated activation, however, Tregs with OX40 costimulation lost their suppressive function. Interestingly, Tregs minimally suppressed the proliferation or the cytokine secretion of Ag-specific CD8(+) T cells after Ag-restimulation. Furthermore, Tregs suppressive function to the antitumor effect was reversed by OX40 costimulation in vivo. Our data indicate that, in addition to controlling effector T-cell function, OX40 costimulation directly controls Treg-mediated suppression in tumor immunity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19455675      PMCID: PMC3018329          DOI: 10.1002/ijc.24435

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  46 in total

1.  Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion.

Authors:  J R Maxwell; A Weinberg; R A Prell; A T Vella
Journal:  J Immunol       Date:  2000-01-01       Impact factor: 5.422

2.  OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.

Authors:  Satoshi Murata; Brian H Ladle; Peter S Kim; Eric R Lutz; Matthew E Wolpoe; Susan E Ivie; Holly M Smith; Todd D Armstrong; Leisha A Emens; Elizabeth M Jaffee; R Todd Reilly
Journal:  J Immunol       Date:  2006-01-15       Impact factor: 5.422

3.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.

Authors:  Jens Dannull; Zhen Su; David Rizzieri; Benjamin K Yang; Doris Coleman; Donna Yancey; Aijing Zhang; Philipp Dahm; Nelson Chao; Eli Gilboa; Johannes Vieweg
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

4.  Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.

Authors:  J Shimizu; S Yamazaki; S Sakaguchi
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

5.  Toll-like receptor 2 controls expansion and function of regulatory T cells.

Authors:  Roger P M Sutmuller; Martijn H M G M den Brok; Matthijs Kramer; Erik J Bennink; Liza W J Toonen; Bart-Jan Kullberg; Leo A Joosten; Shizuo Akira; Mihai G Netea; Gosse J Adema
Journal:  J Clin Invest       Date:  2006-01-19       Impact factor: 14.808

6.  OX40 ligand shuts down IL-10-producing regulatory T cells.

Authors:  Tomoki Ito; Yui-Hsi Wang; Omar Duramad; Shino Hanabuchi; Olivia A Perng; Michel Gilliet; F Xiao-Feng Qin; Yong-Jun Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-21       Impact factor: 11.205

7.  Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.

Authors:  Guangyong Peng; Zhong Guo; Yukiko Kiniwa; Kui Shin Voo; Weiyi Peng; Tihui Fu; Daniel Y Wang; Yanchun Li; Helen Y Wang; Rong-Fu Wang
Journal:  Science       Date:  2005-08-26       Impact factor: 47.728

8.  Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.

Authors:  Peter Attia; Ajay V Maker; Leah R Haworth; Linda Rogers-Freezer; Steven A Rosenberg
Journal:  J Immunother       Date:  2005 Nov-Dec       Impact factor: 4.456

9.  Toll-like receptor 2 signaling modulates the functions of CD4+ CD25+ regulatory T cells.

Authors:  Haiying Liu; Mousa Komai-Koma; Damo Xu; Foo Y Liew
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

10.  Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

Authors:  Kuibeom Ko; Sayuri Yamazaki; Kyoko Nakamura; Tomohisa Nishioka; Keiji Hirota; Tomoyuki Yamaguchi; Jun Shimizu; Takashi Nomura; Tsutomu Chiba; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2005-09-26       Impact factor: 14.307

View more
  28 in total

Review 1.  Harnessing regulatory T cells to suppress asthma: from potential to therapy.

Authors:  Alison N Thorburn; Philip M Hansbro
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-22       Impact factor: 6.914

Review 2.  Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy.

Authors:  Adam J Adler; Payal Mittal; Joseph M Ryan; Beiyan Zhou; Jeffrey S Wasser; Anthony T Vella
Journal:  Immunotherapy       Date:  2017-01       Impact factor: 4.196

3.  Critical role of OX40 signaling in the TCR-independent phase of human and murine thymic Treg generation.

Authors:  Prabhakaran Kumar; Alejandra Marinelarena; Divya Raghunathan; Vandhana K Ragothaman; Shikha Saini; Palash Bhattacharya; Jilao Fan; Alan L Epstein; Ajay V Maker; Bellur S Prabhakar
Journal:  Cell Mol Immunol       Date:  2018-03-26       Impact factor: 11.530

Review 4.  Treg functional stability and its responsiveness to the microenvironment.

Authors:  Joseph Barbi; Drew Pardoll; Fan Pan
Journal:  Immunol Rev       Date:  2014-05       Impact factor: 12.988

Review 5.  OX40 as a novel target for the reversal of immune escape in colorectal cancer.

Authors:  Lin-Hai Yan; Xiao-Liang Liu; Si-Si Mo; Di Zhang; Xian-Wei Mo; Wei-Zhong Tang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

6.  Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.

Authors:  Michael D Oberst; Catherine Augé; Chad Morris; Stacy Kentner; Kathy Mulgrew; Kelly McGlinchey; James Hair; Shino Hanabuchi; Qun Du; Melissa Damschroder; Hui Feng; Steven Eck; Nicholas Buss; Lolke de Haan; Andrew J Pierce; Haesun Park; Andrew Sylwester; Michael K Axthelm; Louis Picker; Nicholas P Morris; Andrew Weinberg; Scott A Hammond
Journal:  Mol Cancer Ther       Date:  2018-03-15       Impact factor: 6.261

7.  Eradication of spontaneous malignancy by local immunotherapy.

Authors:  Idit Sagiv-Barfi; Debra K Czerwinski; Shoshana Levy; Israt S Alam; Aaron T Mayer; Sanjiv S Gambhir; Ronald Levy
Journal:  Sci Transl Med       Date:  2018-01-31       Impact factor: 17.956

8.  Agonist antibodies to TNFR molecules that costimulate T and NK cells.

Authors:  Ignacio Melero; Daniel Hirschhorn-Cymerman; Aizea Morales-Kastresana; Miguel F Sanmamed; Jedd D Wolchok
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

Review 9.  Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer.

Authors:  Julie E Bauman; Robert L Ferris
Journal:  Cancer       Date:  2013-11-12       Impact factor: 6.860

10.  OX40 agonist combined with irreversible electroporation synergistically eradicates established tumors and drives systemic antitumor immune response in a syngeneic pancreatic cancer model.

Authors:  Qi-Wei Zhang; Xiao-Xia Guo; Yu Zhou; Qing-Bing Wang; Qin Liu; Zhi-Yuan Wu; Xiao-Yi Ding
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.